COPENHAGEN, Feb 2 (BestGrowthStock) – Danish drugmaker Novo
Nordisk’s (NOVOb.CO: ) Chief Financial Officer Jesper Brandgaard
said on Tuesday:
* Main reason for the lower fourth-quarter profit (Read more your timing to make a profit.)
yearr-on-year was currency effect.
* Higher fourth-quarter costs due to European Victoza
rollout, increased Japan sales force.
* Company will spend more money on U.S. Victoza launch in
2010 than will earn.
* Company gaining market share in United States in diabetes
products.
* Company is raising dividend to come into line with
international peers.
Stock Market Research
(Reporting by Karin Jensen)
BRIEF-Novo Nordisk says currency effects dented Q4
